Valuation: Centessa Pharmaceuticals plc

Market Cap 626.65Cr 542.49Cr 507.07Cr 463.43Cr 873.31Cr 60TCr 886.96Cr 5.95TCr 2.33TCr 30TCr 2.35TCr 2.3TCr 1LCr P/E 2024
-8.13x
P/E 2025 -17.2x
Enterprise Value 609.03Cr 527.24Cr 492.81Cr 450.4Cr 848.75Cr 58TCr 862.02Cr 5.78TCr 2.27TCr 29TCr 2.29TCr 2.24TCr 97TCr EV / Sales 2024
-
EV / Sales 2025 23,18,10,355x
Free-Float
78.43%
Yield 2024 *
-
Yield 2025 -
1 day+0.80%
3 months+2.30%
6 months+72.12%
Current year+61.94%
Current year 21.5
Extreme 21.5
40.56
1 year 15.01
Extreme 15.01
40.56
3 years 5.15
Extreme 5.15
40.56
5 years 2.88
Extreme 2.885
40.56
10 years 2.88
Extreme 2.885
40.56
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/10/2024
Chief Tech/Sci/R&D Officer 55 01/03/2023
Chief Administrative Officer 58 01/04/2021
Director TitleAgeSince
Director/Board Member - 24/06/2026
Director/Board Member - 24/06/2026
Date Insider Type Main position Quantity % Market Cap.
24/06/26
Medicxi Ventures (Jersey) Ltd.
SellCompany -1,99,63,157 12.9020%
01/05/26 Tax

Chief Executive Officer

-604 0.0004%
02/02/26 Free

Chief Financial Officer

2,26,000 0.1691%
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%-.--%+137.96%+523.08% 626.65Cr
+1.29%+3.09%+6.43%+18.53% 4.95TCr
+0.89%+12.90%+493.60%+590.98% 4.4TCr
+3.08%+14.00%+23.45%+80.73% 3.96TCr
+1.38%+3.32%+33.88%+8.71% 3.93TCr
+0.85%+7.66%+21.22%+48.78% 3.24TCr
+0.08%+4.30% - - 1.68TCr
+1.99%+3.96%+32.51%+122.68% 1.65TCr
+0.34%+2.76%+5.39%+20.43% 1.4TCr
+3.56%+16.87%+81.17%+23.99% 1.28TCr
Average +0.83%+7.14%+92.85%+159.77% 2.71TCr
Weighted average by Cap. +1.03%+7.79%+108.08%+149.11%

Financials

2024 2025
Net sales - 15 12.99 12.14 11.09 20.9 1.43T 21.23 142.33 55.85 715.7 56.32 55.1 2.38T
Net income -24Cr -20Cr -19Cr -17Cr -33Cr -2.25TCr -33Cr -223.7Cr -88Cr -1.12TCr -89Cr -87Cr -3.75TCr -20Cr -17Cr -16Cr -15Cr -28Cr -1.88TCr -28Cr -187.43Cr -74Cr -942.49Cr -74Cr -73Cr -3.14TCr
Net Debt -36Cr -32Cr -29Cr -27Cr -51Cr -3.47TCr -52Cr -345.72Cr -135.66Cr -1.74TCr -136.81Cr -133.83Cr -5.79TCr -18Cr -15Cr -14Cr -13Cr -25Cr -1.68TCr -25Cr -167.19Cr -66Cr -840.7Cr -66Cr -65Cr -2.8TCr
Logo Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Employees
129
  1. Stock Market
  2. Stocks
  3. CNTA Stock